Baidu
map

尿路上皮癌领域必读的2020年关键性研究论文

2021-02-17 MedSci原创 MedSci原创

2021年欧洲泌尿外科协会(EAU)肿瘤泌尿科(ESOU)虚拟年会的“ 2020年泌尿外科肿瘤必读论文”包括Thomas Seisen博士对尿路上皮文献中重要论文的全面总结。

2021年欧洲泌尿外科协会(EAU)肿瘤泌尿科(ESOU)虚拟年会的“ 2020年泌尿外科肿瘤必读论文”包括Thomas Seisen博士对尿路上皮文献中重要论文的全面总结。 第一篇文章为DaBlaCa-13研究,该研究旨在评估与复发性非肌肉浸润性膀胱癌(NMIBC)患者相比,使用丝裂霉素C进行短期,密集化学疗法与辅助输注相比的肿瘤反应和不良事件。 干预组(59例)患者每周3次随机分组接受丝裂霉素C,共2周(59例),对照组采用经尿道膀胱肿瘤切除术(TURBT)和每周6剂辅助滴注(61例)。主要结果是肿瘤反应,治疗4周后通过柔性膀胱镜检查在干预组进行评估。 DaBlaCa-13试验发现,干预组的33名参与者(57%)观察到了完全的肿瘤反应,并且干预组中报告的不良事件少于对照组。 鉴于化学切割在57%的患者中产生了肿瘤反应,因此这些结果具有启发性,因此只有一半接受化学切割治疗的患者确实需要TURBT。 第二篇文章为NIMBUS III期试验,在2020年的《欧洲泌尿外科杂志》上发表,该研究通过标准数量和剂量的卡介苗-加仑(Bacillus Calmette-Guérin)(BCG)滴注与

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1196450, encodeId=9a6011964504e, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56a05417709, createdName=ms3000000301976572, createdTime=Wed Feb 23 15:55:23 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954207, encodeId=0df195420e55, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5c0c541ffceb4f11b0948c3e262b6e70/5b6894da824e43cca0ba37dddeca4910.jpg, createdBy=f45a2515633, createdName=药师小王, createdTime=Tue Apr 06 14:50:26 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Fri Feb 19 07:24:52 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925147, encodeId=f6bb92514ee0, content=好文必读<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47516, encryptionId=c3aa4e516d6, topicName=尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:09 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925096, encodeId=0b4e925096c1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:55:30 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2022-02-23 ms3000000301976572

    好文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1196450, encodeId=9a6011964504e, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56a05417709, createdName=ms3000000301976572, createdTime=Wed Feb 23 15:55:23 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954207, encodeId=0df195420e55, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5c0c541ffceb4f11b0948c3e262b6e70/5b6894da824e43cca0ba37dddeca4910.jpg, createdBy=f45a2515633, createdName=药师小王, createdTime=Tue Apr 06 14:50:26 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Fri Feb 19 07:24:52 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925147, encodeId=f6bb92514ee0, content=好文必读<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47516, encryptionId=c3aa4e516d6, topicName=尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:09 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925096, encodeId=0b4e925096c1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:55:30 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-04-06 药师小王

    好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1196450, encodeId=9a6011964504e, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56a05417709, createdName=ms3000000301976572, createdTime=Wed Feb 23 15:55:23 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954207, encodeId=0df195420e55, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5c0c541ffceb4f11b0948c3e262b6e70/5b6894da824e43cca0ba37dddeca4910.jpg, createdBy=f45a2515633, createdName=药师小王, createdTime=Tue Apr 06 14:50:26 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Fri Feb 19 07:24:52 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925147, encodeId=f6bb92514ee0, content=好文必读<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47516, encryptionId=c3aa4e516d6, topicName=尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:09 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925096, encodeId=0b4e925096c1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:55:30 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1196450, encodeId=9a6011964504e, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56a05417709, createdName=ms3000000301976572, createdTime=Wed Feb 23 15:55:23 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954207, encodeId=0df195420e55, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5c0c541ffceb4f11b0948c3e262b6e70/5b6894da824e43cca0ba37dddeca4910.jpg, createdBy=f45a2515633, createdName=药师小王, createdTime=Tue Apr 06 14:50:26 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Fri Feb 19 07:24:52 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925147, encodeId=f6bb92514ee0, content=好文必读<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47516, encryptionId=c3aa4e516d6, topicName=尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:09 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925096, encodeId=0b4e925096c1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:55:30 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 健康达人

    好文必读#尿路上皮癌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1196450, encodeId=9a6011964504e, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56a05417709, createdName=ms3000000301976572, createdTime=Wed Feb 23 15:55:23 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954207, encodeId=0df195420e55, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201120/5c0c541ffceb4f11b0948c3e262b6e70/5b6894da824e43cca0ba37dddeca4910.jpg, createdBy=f45a2515633, createdName=药师小王, createdTime=Tue Apr 06 14:50:26 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20027, encryptionId=0e802002e45, topicName=上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=866a13134648, createdName=mashirong, createdTime=Fri Feb 19 07:24:52 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925147, encodeId=f6bb92514ee0, content=好文必读<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47516, encryptionId=c3aa4e516d6, topicName=尿路上皮癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=健康达人, createdTime=Wed Feb 17 22:19:09 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925096, encodeId=0b4e925096c1, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Feb 17 17:55:30 CST 2021, time=2021-02-17, status=1, ipAttribution=)]
    2021-02-17 jyzxjiangqin

    好文章!

    0

相关资讯

荣昌生物纬迪西妥单抗(RC48)治疗尿路上皮癌获FDA突破性疗法认定

近日,荣昌生物制药(烟台)股份有限公司(RemeGen)宣布自主研发的抗体-药物偶联(ADC)药物注射用纬迪西妥单抗(Disitamab vedotin,商品名:爱地希®,研究代号:RC48)获得美国

Nat Med:不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法

免疫检查点疗法正在对局部尿路上皮癌患者进行新辅助治疗测试,其中一项研究报告了接受抗PD-L1单药治疗的顺铂治疗不适合患者的相关数据。该研究报道,肿瘤体积大的患者(已知的大于临床T2疾病高危特征)治疗响

ASCO GU 2021:上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新

上尿路尿路上皮癌(UTUC)包括肾盂癌和输尿管癌,与膀胱癌同属尿路上皮癌。UTUC发病年龄多为50~70岁,占全部尿路上皮癌的5%~10%,而在中国这一比例可能更高,且肿瘤侵袭性高、预后差,术后仍有2

ASCO GU 2021:固定剂量的Durvalumab单药治疗尿道肿瘤具有良好的安全性(STRONG研究)

对于泌尿生殖系统肿瘤学家治疗的肿瘤,晚期尿路上皮癌的预后最差,标准治疗为接受铂类诱导化疗。但是,即使采用这种疗法,由于化疗耐药性的发展,其复发率和疾病进展仍然很高,并且总生存期仍然很短。

ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布(IMvigor130研究)

Atezolizumab(anti-PD-L1)单一疗法已被批准用于不符合顺铂治疗要求的患者,这些患者的局部或晚期转移性尿路上皮癌中PD-L1表达的免疫细胞≥肿瘤面积的5%(每VENTANA S

ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布(EV-301研究)

顺铂化疗是晚期尿路上皮癌患者的医疗标准。由于表现低下,肾功能不全或其他合并症,这些患者中多达50%在医学上不符合顺铂治疗的资格。免疫检查点封锁是肿瘤不表达PD-L1的不铂类患者或卡铂类患者的一线治疗选

Baidu
map
Baidu
map
Baidu
map